Warts: Symptoms, Causes, Diagnosis & Treatment

Warts are circumscribed epidermal proliferations produced when oncogenically quiet HPV genotypes (for common skin warts, classically types 1, 2, 4, 27, 57 among others) establish infection in the basal and spinous layers after micro-abrasion. Viral replication drives acanthosis, papillomatosis and coarse hyperkeratosis, yielding a firm papule or plaque that interrupts normal skin markings on palms and soles. Host cellular immunity eventually recognises early viral proteins, which explains the high spontaneous regression rate in immunocompetent children despite minimal intervention.

Clinicians separate cutaneous disease from mucosal high-risk HPV pathways: common verrucae rarely harbour the oncotype profile seen in persistent cervical or anal infection, yet immunosuppression blurs that comfort—extensive verrucous change can mask or coexist with squamous neoplasia, so the nursing mindset stays alert to evolving morphology rather than treating every lesion as a benign cosmetic nuisance.

↔On a small screen, swipe or scroll sideways to see the full table.

Most uncomplicated verrucae are painless apart from mild tightness when hyperkeratosis thickens. Plantar lesions translate into focal burning with weight transfer; children may limp or refuse PE before any visible limp is obvious to carers. Periungual lesions disturb nail growth and create chronic paronychia-like erythema that overlaps cellulitis when bacterial superinfection intervenes.

Typical presentation

• Rough hyperkeratotic papule with interrupted dermatoglyphics on palms or soles.
• Clustered mosaic pattern on the heel rather than a solitary papule.
• Low-grade rash-like scattering of plane warts on the face of adolescents.

Atypical or high-burden cues

• Thousands of new lesions in an immunosuppressed host—think therapeutic modulation and biopsy sampling rather than repeated over-the-counter acid alone.
• Pigmented, ulcerated or fixed plaque in sun-damaged skin—treat as possible malignancy until proven otherwise.
• Deep fissuring with lymphangitic streaking—overlap infection pathways distinct from uncomplicated HPV.

HPV enters through microscopic epithelial breaks acquired during nail biting, shaving, athletic abrasions, or maceration on pool decks. Viral particles shed from desquamated skin scales; warm, moist environments prolong viability on fomites. Host polymorphisms and local immune milieu determine whether infection becomes a single regressing papule versus a persistent mosaic plaque.

Modifiable contributors

• Trauma from footwear, occupational tools, or cosmetic shaving—especially with shared razors.
• Untreated eczema or psoriasis plaques that provide Koebner sites.
• Moist occlusion without scheduled skin checks in athletes.

Non-modifiable or structural contributors

• Age—peak incidence in school years.
• Immunosuppressive therapy or inherited immune deficits.
• Prior HPV exposure does not grant sterile immunity; reinfection is possible.

Clinical assessment

Diagnosis remains overwhelmingly clinical: rough surface, punctate haemorrhage on gentle paring, and location match HPV far more often than exotic dermatoses. Use dermoscopy where available to highlight regular dotted vessels versus chaotic vascular loops seen in some skin cancers.

Laboratory investigations

Routine serology is unnecessary. For anogenital lesions, follow local STI panels—syphilis serology belongs in the differential of broad-based plaques, and HIV status informs healing expectations. HPV nucleic acid testing supports cervical screening programmes but does not replace examination of visible external warts.

Imaging

Not indicated for uncomplicated verrucae. MRI reserved for giant Buschke-Löwenstein-type tumours or suspected deep invasion—tertiary centre decisions.

Diagnostic criteria / scoring

No universal score is required; instead document size (mm), number, mosaic pattern, pain (0–10), impact on gait or dexterity, and prior therapies—this narrative guides insurance prior authorisations and specialist referrals.

When to biopsy

Reserve skin biopsy for treatment-refractory lesions, uncertain pigmentation, or immunosuppressed patients where squamous cell carcinoma cannot be excluded on clinical grounds alone.

• Corns/clavus—pain centred on a bony prominence, smooth translucent core without thrombosed dots.
• Fungal nail infection—subungual debris with dermatophyte pattern on microscopy rather than verrucous papules.
• Genital herpes—grouped vesicles evolving to tender ulcers; PCR where available.
• Seborrheic keratosis—stuck-on waxy plaque in older adults; lacks punctate bleeding on gentle paring.
• Squamous cell carcinoma / keratoacanthoma—exponential growth, central crater, tenderness—urgent dermatology.

First-line management

High-concentration salicylic acid remains the pragmatic home backbone: soften hyperkeratosis with soaking, pare sparingly with sterile instruments, protect surrounding skin with petrolatum barrier, and reapply acid per product instructions—usually daily or alternate days. Pair education with written steps; literacy and manual dexterity issues frequently explain apparent treatment failure.

Cryotherapy using liquid nitrogen freezes infected epithelium and provokes a controlled blister; typical intervals are every two to three weeks. Warn about post-inflammatory pigment change, especially in richly pigmented skin, and document informed discussion.

Second-line / specialist modalities

• Imiquimod, podophyllotoxin or sinecatechins for selected mucosal or extensive cutaneous cases per specialist prescription.
• Photodynamic therapy, laser ablation, curettage with cautery for refractory mosaic plantar disease.
• Intralesional bleomycin or 5-fluorouracil in recalcitrant periungual warts under dermatology governance.

Special populations

Pregnancy: defer podophyllin; cryotherapy or limited salicylic acid per specialist advice. Diabetes: prioritise off-loading and neuropathy-safe paring. Children: emphasise pain-minimising strategies and school participation with covered lesions.

Clinical decision flow (summary)

1. Confirm stable vitals and absence of spreading bacterial infection.
2. Classify wart subtype, burden, pain score, occupational impact.
3. Select keratolytic versus destructive modality; set review date at 2–3 weeks.
4. Escalate if morphology changes, function is threatened, or three guideline-concordant cycles fail.

Monitoring intervals: fortnightly while active therapy is uptitrating, then monthly until clearance; photograph lesions with a ruler in frame. Treatment failure means expansion, new satellite lesions despite adherence, or functional loss—refer to dermatology or podiatry rather than stacking unsupervised home acids.

Drug–drug and safety checks: salicylate toxicity is negligible with focal cutaneous use but avoid widespread occlusion in infants. Document cryotherapy contraindications such as cold urticaria or poor circulation when known.

• Post-inflammatory hyper- or hypopigmentation after cryotherapy or inflammation.
• Nail dystrophy from periungual matrix injury.
• Chronic pain and altered gait mechanics from neglected plantar plaques.
• Psychosocial stigma, especially facial or anogenital involvement.
• Rare malignant transformation in longstanding immunosuppression—maintain low threshold for biopsy.

Public-health HPV vaccination reduces future vaccine-type anogenital and oncogenic risk but does not treat existing verrucae. Clinically relevant prevention for ward and community nurses includes reinforcing footwear, discouraging shared pedicure instruments, covering open lesions during patient contact per occupational policy, and optimising control of barrier diseases that invite Koebnerisation.

Immunocompetent children frequently clear lesions without aggressive therapy; adults—especially smokers or those with plantar mosaic disease—may require multiple modalities across months. Set realistic expectations: even successful cryotherapy often needs three to six sessions. Mucosal high-risk HPV outcomes depend on cancer-screening participation rather than topical wart therapies.

Language matters: calling a facial lesion a "wart" without biopsy reassurance can delay cancer detection—use neutral terms like "hyperkeratotic papule" when uncertainty exists. Teach carers to photograph rather than pick, and align school letters with infection-control reality: verrucae do not trigger the same school-exclusion rules as superficial bacterial skin infections such as impetigo, yet pool hygiene still warrants covered lesions.

Bedside checklist

• Measure lesion dimensions and pain score; note footwear type.
• Inspect nails, web spaces and contralateral foot for satellite lesions.
• Review diabetes neuropathy status before endorsing sharp paring at home.
• Confirm STI risk assessment completed when lesions extend to groin or perianal skin.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response and matrix matching on the topic of HPV wart recognition, keratolytic teaching, cryotherapy safety, STI risk and complication surveillance—mirroring Clinical Judgment Measurement Model layers from cue analysis through evaluation of outcomes.